New Milestone for TB Drug Development
26th August 2011
The start of Phase IIb trials of the MVA85A vaccine and related technology, licensed by Oxford University Innovation to OETC Ltd. in 2008, has been announced.
Aeras and the Oxford-Emergent Tuberculosis Consortium (OETC) have announced the start of a Phase IIb proof-of-concept efficacy trial of a new investigational Tuberculosis (TB) vaccine that involves people living with the human immunodeficiency virus (HIV). The MVA85A vaccine was originally developed at the University of Oxford by Dr. Helen McShane, a Wellcome Trust Senior Clinical Research Fellow, working with Dr. Sarah Gilbert, a Reader in Vaccinology, and Professor Adrian Hill, a Wellcome Trust Principal Research Fellow.
© Oxford University Innovation